No Data
No Data
Notable Healthcare Headlines for the Week: UnitedHealth, Eli Lilly, J&J in Focus
Baird Maintains Charles River(CRL.US) With Hold Rating, Raises Target Price to $118
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
Short Bets Against S&P 500 Healthcare Stock Rises in March; MRNA Stays Top Shorted
Charles River Associates (CRA) to Host First-Quarter Fiscal 2025 Financial Results Conference Call on May 1
Express News | Charles River Laboratories International Inc : Baird Raises Target Price to $118 From $101